Dapagliflozin vs. Canagliflozin: SGLT2 Inhibitors for Heart, Kidney, and Diabetes
Dapagliflozin (DAPAGLIFLOZIN) and Canagliflozin (INVOKANA) are both SGLT2 inhibitor medications primarily used to manage type 2 diabetes, heart failure, and chronic kidney disease. They work similarly by helping the kidneys remove sugar from the body, but they have some differences in their specific approved uses and patient populations.
Side-by-Side Comparison
| Category | Dapagliflozin | Canagliflozin |
|---|---|---|
| Drug Class | SGLT2 Inhibitor | SGLT2 Inhibitor |
| Primary Uses | Chronic kidney disease (to reduce risk of progression, cardiovascular death, hospitalization for heart failure), cardiovascular death, and hospitalization for heart failure. | Type 2 diabetes (adults and pediatric patients 10+), reduce risk of major adverse cardiovascular events (CV death, nonfatal MI, nonfatal stroke), reduce risk of end-stage kidney disease, CV death, and hospitalization for heart failure in type 2 diabetes. |
| Specific Kidney Indication | Approved to reduce risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. | Approved to reduce the risk of end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes and diabetic nephropathy. |
| Pediatric Use | Not specified in provided text. | Approved for pediatric patients aged 10 years and older with type 2 diabetes mellitus. |
| Mechanism of Action | Inhibits SGLT2 in the kidneys, reducing glucose reabsorption. | Inhibits SGLT2 in the kidneys, reducing glucose reabsorption. |
| Key Warning | Diabetic Ketoacidosis in Type 1 Diabetes and Other Ketoacidosis. | Diabetic Ketoacidosis in Type 1 Diabetes and Other Ketoacidosis. |
| When to Choose | A doctor might prefer Dapagliflozin if the primary concern is chronic kidney disease progression, regardless of diabetes status, or for reducing the risk of cardiovascular death and heart failure hospitalization. Its broad kidney indication makes it a strong choice for kidney protection. | Canagliflozin might be preferred for adults and children (10+) with type 2 diabetes who need improved glycemic control, or for those with type 2 diabetes who are at high risk for major cardiovascular events or have diabetic kidney disease. Its specific approval for younger diabetic patients is a distinguishing factor. |
| Side Effects | Both drugs share common side effects typical of SGLT2 inhibitors, such as an increased risk of urinary tract infections, yeast infections, and dehydration. A serious but less common risk for both is diabetic ketoacidosis, especially in patients with type 1 diabetes or other risk factors. | |
| Cost | Both Dapagliflozin and Canagliflozin are available as brand-name prescription medications. Generic versions are not widely available for either drug, meaning they can be relatively expensive, though patient assistance programs or insurance coverage may help with costs. |
Bottom Line
Dapagliflozin and Canagliflozin are effective SGLT2 inhibitors offering significant benefits for patients with type 2 diabetes, heart failure, and chronic kidney disease. The choice between them often depends on the specific indications, patient's age (especially for pediatric diabetes), and the primary health condition being addressed, always in consultation with a healthcare provider.
Dapagliflozin Overview
Dapagliflozin (brand name: DAPAGLIFLOZIN) is a medication that helps your kidneys remove excess sugar from your body. It is used to treat type 2 diabetes, heart failure, and chronic kidney disease by improving blood sugar control and protecting your heart and kidneys.
Full Dapagliflozin guide →Canagliflozin Overview
Invokana (canagliflozin) is a medication for adults and children aged 10 and older with type 2 diabetes. It helps lower blood sugar by causing the kidneys to remove more sugar from the body through urine. For adults with type 2 diabetes and existing heart or kidney disease, Invokana also helps reduce the risk of serious heart problems, hospitalization for heart failure, and progression of kidney disease.
Full Canagliflozin guide →Compare prices for Dapagliflozin and Canagliflozin
Check real-time pharmacy prices before you fill — free, no account needed.
Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.